Novartis AG (NYSE:NVS), a Switzerland-based manufacturer of healthcare products, said Friday that it has launched an in-office point of care diagnostic tool Niji System and Total IgE Test. The test measures immunoglobulin E (IgE) levels in an in-office diagnosis setting of IgE-mediated allergic disorders in conjunction with other clinical findings. The test can help identify patients with uncontrolled asthma mediated by IgE. The system is now cleared for sale in the European Union and in all other countries recognizing the CE Mark. The company intends to launch the system in Europe in Q4 2016.
About 1.29 million shares traded hands or 1.57% up from the average. Novartis AG (ADR) (NYSE:NVS) has risen 9.70% since February 8, 2016 and is uptrending. It has underperformed by 6.79% the S&P500.
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products.
The company has a market cap of $209.41 billion. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. It has a 28.61 P/E ratio. The Company’s divisions include Pharmaceuticals, Alcon and Sandoz.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.